United Health Products Forms Medical Advisory Board

Henderson, Nevada – March 19, 2018 – United Health Products, Inc. (OTCQB: UEEC),manufacturer and marketer of HemoStyp®, a patented hemostatic gauze for the healthcare and wound care sectors, is pleased to announce the formation of a Medical Advisory Board.  Joining this newly formed Board are: 

Gerard Abate, MD Former Executive Director, Medical Affairs for Fortune 500 company Quest Diagnostics, where he directed 80+ Medical Affairs group that includes 8 clinical franchise medical directors, (oncology, genetics, women’s health, cardiovascular-metabolism, neurology, infectious disease/inflammation),HEOR team, publications group, MSLs, genetic counselors and project management.

Joseph M. Chalil, MD Senior Medical Director, Medical Affairs, North America, DBV Technologies SA, Montrouge France and New York NY, a clinical-stage bio-pharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin®.

Michael Erik Jessen, MD Professor and Chairman, and Frank M. Ryburn, Jr. Distinguished Chair in Cardiothoracic Surgery and Transplantation, Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center.

Richard Massoth, DDS, MSD received his specialty training in Endodontics and his Masters of Science in Dentistry from Boston University in 1982. He has been an Adjunct Professor at the UCLA School of Dentistry and has been in clinical practice for 36 years. Dr. Massoth has been a published author, a frequent symposium speaker, and a leader serving in various positions in organized dentistry.

David W. Ramey DVM Thirty-four years of clinical experience as a full-time practitioner: Written thirteen books on various aspects of equine health, five book chapters, and have had over seventy papers published in professional journals. Frequent speaker: Invited podium speaker, lecturing on various topics in universities, conventions, and continuing education seminars around the United States, as well as Canada, Australia, and the UK.

Zachariah P. Zachariah, MD Medical Director, UHealth Cardiology Fort Lauderdale. Clinical Faculty, Department of Cardiology, University of Miami. Board member Florida Board of Governors. Member Board of Trustees, Chairman, Technology  Transfer  Committee Member- Executive Committee. Member, Academic Affairs & Strategic Planning Committee, Nova Southeastern University.

As the company continues to pursue its application to have HemoStyp approved for clinical use in the United States and South Korea, it looks forward to calling upon these experts in the fields of medicine, veterinary medicine and dental medicine to pursue various opportunities in these different markets. Douglas K. Beplate, CEO, UHP, said,” We are extremely pleased to have such highly regarded thought leaders join and work with us to help advance the company to the next stage of development.”  Visit the company’s website for the complete bios of the Medical Advisory Board.

Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.

Company Contact:
United Health Products, Inc.

IR Contact:
PAN Consultants Ltd.
Philippe Niemetz